RecensMedical, Inc. (394420.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
4,245.00 KRW
Market cap
46.06 bn KRW
P/E (2025)
–
P/S (2025)
5.22
Dividend yield
0.00 %
Net margin
-216.56 %
Return on equity (ROE)
-274.03 %
Return on assets (ROA)
-159.24 %

RecensMedical, Inc. financials

Fiscal year20242025
Revenue6.26 bn KRW8.83 bn KRW
Gross profit1.37 bn KRW4.33 bn KRW
Operating income-14.16 bn KRW-10.64 bn KRW
EBIT-3.95 bn KRW-16.71 bn KRW
Net income-7.84 bn KRW-19.12 bn KRW
Diluted EPS – continuing operations-722.90 KRW-1,762.07 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About RecensMedical, Inc.

RecensMedical, Inc. operates as a medical device company specializing in precision cooling therapy and transdermal drug delivery solutions. The company engages in the development of precision medical cooling device in the fields of ophthalmology and dermatology. The company's products include OcuCool, a hand-held, cooling anesthesia device that provides rapid and controlled cooling to the conjunctiva and sclera, and TargetCool, a handheld device that delivers rapid, precise, and controlled cooling to the skin tissue for the temporary reduction of pain, swelling, inflammation, and hematoma from minor surgical procedures, minor sprains or other minor sports injuries. Additionally, it offers TargetCool+, a spray syringe; and VetEase, a spray syringe for animals. Its portfolio of clinical program includes ocular anesthesia, actinic keratosis, eczema, rosacea, prurigo nodularis, and atopic dermatitis. The company was founded in 2016 and is based in Hwaseong-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.